Laura Stoppel

CIK: 0001865119

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ARTV

Artiva Biotherapeutics, Inc.

Director

ABOS

Acumen Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

ARTV
Artiva Biotherapeutics, Inc.
Sep 10, 2026
Award(A)
Director Stock Option (Right to Buy)
Direct
16.3K shares-
ARTV
Artiva Biotherapeutics, Inc.
Sep 8, 2026
Award(A)
Director Stock Option (Right to Buy)
Direct
13.8K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jun 3, 2026
Award(A)
Direct
35.5K shares-
ARTV
Artiva Biotherapeutics, Inc.
Jun 24, 2025
Award(A)
Director Stock Option (Right to Buy)
Direct
13.8K shares-
ABOS
Acumen Pharmaceuticals, Inc.
Jun 4, 2025
Award(A)
Direct
12.8K shares-

		Type	Shares	Price		Ownership
Sep 10, 2026	ARTV Artiva Biotherapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	16,250	-	-	Direct
Sep 8, 2026	ARTV Artiva Biotherapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	13,750	-	-	Direct
Jun 3, 2026	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	35,500	-	$0	Direct
Jun 24, 2025	ARTV Artiva Biotherapeutics, Inc.	Award(A) Director Stock Option (Right to Buy)	13,750	-	-	Direct
Jun 4, 2025	ABOS Acumen Pharmaceuticals, Inc.	Award(A)	12,800	-	-	Direct

1-5 of 5 transactions

About Stoppel Laura

Stoppel Laura (SEC CIK 0001865119) files insider reports with the SEC as Director of Artiva Biotherapeutics, Inc. (ARTV) and Director of Acumen Pharmaceuticals, Inc. (ABOS).

Signal8 holds 5 ownership filings by Stoppel Laura, all Form 4s, filed between Jun 5, 2025 and Sep 14, 2026. Those filings report 5 transactions, from Jun 4, 2025 to Sep 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Stoppel Laura's filings is in SAN DIEGO, CA.

Recent filings by Stoppel Laura

Sep 10, 2026: Grant or award of ARTV derivative securities (Form 4, code A).
Sep 8, 2026: Grant or award of ARTV derivative securities (Form 4, code A).
Jun 3, 2026: Grant or award of ABOS shares (Form 4, code A).
Jun 24, 2025: Grant or award of ARTV derivative securities (Form 4, code A).
Jun 4, 2025: Grant or award of ABOS shares (Form 4, code A).

Other insiders filing for Artiva Biotherapeutics, Inc. (ARTV)

Aslan Fred, Chief Executive Officer
Horan Christopher, Chief Tech Operations Officer
Bush Jennifer, COO, CLO, Compliance Officer
Banerjee Subhashis, Chief Medical Officer
RA CAPITAL MANAGEMENT, L.P., Director
Sorg Elaine K., Director

How to read Form 4 transaction codes